Gilead moves into oral IL-23 blockade with a $1.275 billion bet
Gilead Sciences is paying $1.275 billion upfront to acquire PepStar Therapeutics’ oral IL-23 receptor inhibitor program, a move aimed squarely at a market already shaped by injectable and oral competitors in inflammatory disease. The centerpiece of the deal, HCXT-2001, is still in phase 1 development, but the structure of the transaction makes the strategic intent clear: Gilead wants a place in a class that has become commercially important and biologically validated.
The appeal is obvious. IL-23 has become one of the most commercially productive immune targets in medicine because it sits upstream in inflammatory signaling pathways that drive several chronic diseases. By interrupting that axis, drug developers can blunt pathologic immune activation in diseases ranging from plaque psoriasis to inflammatory bowel disease. In the current market, AbbVie’s Skyrizi and Johnson & Johnson’s Icotyde have already established the value of that biology, while Gilead is now positioning itself to compete with a molecule designed for oral use.
The acquired asset is an oral macrocyclic peptide inhibitor of the IL-23 receptor. Macrocyclic peptides occupy an unusual space between small molecules and biologics: they can be engineered to retain target selectivity while still surviving the digestive tract well enough to reach systemic circulation. The challenge has never been whether the biology matters. The challenge has been whether the peptide can be formulated to behave reliably after swallowing, where enzymes, pH changes, and variable food intake can alter exposure.
Food effects are central to this story. Studies already registered in China are assessing HCXT-2001 in healthy volunteers and examining how food changes its absorption. One of those trials is evaluating single doses of “HCXT-2001 Tablets (A),” while a third study enrolling healthy adults in New Zealand is testing both “HCXT-2001 Tablets” and “HCXT-2001 Tablets (A).” Those details may look technical, but they are exactly the hurdles that decide whether an oral peptide advances from an intriguing pharmacology project to a practical medicine.
This is where the competition becomes more than a commercial comparison. J&J’s Icotyde has already shown that oral macrocyclic peptides can reach clinically relevant immune targets, but the class comes with a dosing burden. Patients must wait at least 30 minutes after taking Icotyde before eating. Merck’s Lipfendra carries the same restriction. A drug that preserves efficacy while easing meal timing, reducing dosing frequency, or improving combination flexibility would have a meaningful advantage in day-to-day use.
Less frequent dosing may become one of HCXT-2001’s most important differentiators if the phase 1 program supports it. PepStar appears to have extended the half-life of the molecule, and the first phase 1 trial may test both daily and weekly administration during its multiple-ascending-dose stage. A weekly oral IL-23 receptor inhibitor would be unusual and clinically attractive, because chronic inflammatory diseases often require long-term adherence, and adherence tends to fall when treatment is inconvenient. In practical terms, a tablet is only as useful as the regimen built around it.
BMO Capital Markets described the acquisition as a logical complement to emvistegrast and suggested it could support a potential all-oral combination strategy. Emvistegrast, Gilead’s inhibitor of the α4β7 pathway, recently posted an impressive phase 2 result. The therapeutic logic is straightforward: if one oral agent suppresses IL-23-driven inflammation and another modulates gut-homing immune trafficking through α4β7, the two mechanisms could, in theory, be paired for diseases where both systemic and mucosal immune activity matter. That kind of combination design is especially relevant in inflammatory bowel disease, where single-pathway control often leaves residual disease activity.
IL-23 is implicated in a wide range of immune-mediated inflammatory diseases, which explains why companies continue to invest heavily in this target despite a crowded field. Gilead is not buying a late-stage de-risked asset; it is buying a platform-level opportunity before human data have proved the concept. That timing also means the remaining questions are fundamental: how much drug exposure is achieved after oral dosing, how variable is absorption with meals, how durable is receptor inhibition, and whether the safety profile supports chronic use.
The commercial context makes the risk easier to understand. Skyrizi has delivered nearly $10 billion for AbbVie over the first half of the year, while J&J has emphasized Icotyde’s launch without releasing sales figures. Those numbers are not just a signal of market size; they show how much value investors and manufacturers now attach to IL-23 inhibition. A successful oral entrant would not need to replace established biologics immediately. It would only need to carve out a meaningful niche in patients who prefer oral therapy, want combination options, or face barriers to injection-based treatment.
Pathophysiologically, the attraction of IL-23 blockade lies in its position within inflammatory cascades that sustain pathogenic T-cell responses. Interrupting that signal can reduce downstream cytokine amplification, dampen tissue inflammation, and ease the chronic immune activation that drives plaques, bowel inflammation, and arthritis-associated manifestations. Oral delivery does not change the biology of the pathway, but it could change how early, how conveniently, and how consistently that biology is targeted in real-world care.
For now, HCXT-2001 remains an early-phase asset with a long road ahead. The next inflection points will come from pharmacokinetic data, food-effect readouts, and dose-escalation results in healthy volunteers. Those studies will decide whether Gilead’s $1.275 billion wager buys more than optionality. The unanswered questions sit in the data still to come: whether oral IL-23 blockade can deliver stable exposure, whether weekly dosing is feasible, and whether the molecule can separate itself from the meal restrictions that still define this class.